Articles related to COMBINATION THERAPY

The FDA’s recent approval of toripalimab, based on the JUPITER-02 and POLARIS-02 clinical trials, marks a significant milestone in the treatment of nasopharyngeal carcinoma. With a median progression-free survival of 11.7 months, toripalimab has shown promising results in improving patient outcomes.

The recent phase 1/2 study of Pfizer-BioNTech’s combination vaccine candidate demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. This promising development could significantly impact global immunization practices.

The approval of Combogesic IV, backed by data from two phase 3 studies, signifies a major breakthrough in our ongoing efforts to provide effective and safer alternatives to opioids for postoperative pain management.

This recent study suggests that systemic treatment with chemotherapy plus immunotherapy may allow patients with muscle-invasive bladder cancer (MIBC) to avoid radical cystectomy.

The FDA’s recent approval of Pombiliti + Opfolda just expanded treatment options for the rare inherited lysosomal disorder.

The FDA approval of motixafortide in combination with filgrastim offers a new, evidence-based approach to improve stem cell mobilization in multiple myeloma patients undergoing ASCT.